Results 121 to 130 of about 19,833 (262)

Does DPP-4 inhibitor treatment affect the clinical outcomes of COVID-19 in type 2 diabetes mellitus patients? [PDF]

North Clin Istanb, 2022
Erol RS, Sen EC, Ozturk FY, Sarac Z, Kokoglu GL, Canat MM, Yildiz D, Aytekin YE, Sevgi DY, Altuntas Y.   +9 more
europepmc   +1 more source

Quality of Diabetes Care Among Older Adults in Germany—Results of the Study on Health of Older People 2022/2023 Compared With Previous National Health Surveys

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims The study aims (1) to evaluate the quality of diabetes care considering guideline‐recommended medical therapies, cardiometabolic factors, and self‐management of health behaviours among older adults with diabetes in Germany, and (2) to examine time trends.
Yong Du, Giselle Sarganas, Beate Gaertner, Maike Buchmann, Judith Fuchs, Hannelore Neuhauser, Christin Heidemann   +6 more
wiley   +1 more source

Gingival-Dominant Presentation of DPP-4 Inhibitor-Associated Bullous Pemphigoid: A Case Report. [PDF]

Cureus
Fujii Y, Kataoka T, Togashi C, Ishikawa M, Kawase-Koga Y.   +4 more
europepmc   +1 more source

Comparison of DPP-4 Inhibitors

The Journal of Korean Diabetes, 2013
Nam Hoon Kim, Sin Gon Kim
openaire   +1 more source

Bowel Obstruction/Ileus Associated With the Use of Glucagon‐Like Peptide‐1 Receptor Agonists: A Nationwide Database Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims The association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) use and the development of bowel obstruction/ileus remains unclear, and evidence for specific bowel obstruction/ileus subtypes remains limited. We examined the association between GLP‐1RA use and the incidence of bowel obstruction/ileus subtypes across different ...
Yuichiro Matsuo, Akira Okada, Takashi Sakamoto, Hideo Yasunaga   +3 more
wiley   +1 more source

Preclinical pharmacological profiles of cofrogliptin, a novel and bi-weekly DPP-4 inhibitor. [PDF]

Front Pharmacol
Gou X, Dou C, Tang P, Zheng X, Zhang C, Wang J, Meng Q, Wang J.   +7 more
europepmc   +1 more source

Cost and clinical impact of a nonmedical DPP-4 inhibitor switch in patients with diabetes. [PDF]

J Manag Care Spec Pharm, 2021
Kheloussi S, Johns A, Parente V, McLay W, Gionfriddo MR.   +4 more
europepmc   +1 more source

The Upfront Effectiveness of a 6‐Week Continuous Glucose Monitoring Intervention for Non‐Insulin‐Using Individuals With Type 2 Diabetes Is No Longer Detectable at 6–12 Months: An Observational Follow‐Up of a Randomized Trial Cohort

Diabetes, Obesity and Metabolism, EarlyView.
Jiawei Ryan Zhang, Roseanne O. Yeung, Donna P. Manca, Pratima Singh, Inga Olu‐Jordan, Tawnya Perry, Gulelala Rahim, Evan M. Hagen, Darren Lau   +8 more
wiley   +1 more source

Hospitalisation Is a Strong Risk Factor for Discontinuation of Sodium‐Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Sodium–glucose cotransporter 2 inhibitors (SGLT2i) are commonly withheld during hospitalisation because of concerns about diabetic ketoacidosis. We examined whether hospitalisation was associated with discontinuation of SGLT2i and compared patterns with another anti‐hyperglycaemic medicine without similar inpatient safety concerns ...
Tamara Y. Milder, Leah Shepherd, Hans Kristian Raket, Jerry R. Greenfield, Richard O. Day, Jialing Lin, Juliana de Oliveira Costa, Sophie Stocker, Carol A. Pollock, Brendon Neuen, Min Jun, Jane Ludington, Sallie‐Anne Pearson, Michael O. Falster   +13 more
wiley   +1 more source

Successful management of DPP-4 inhibitor-induced bullous pemphigoid with Stapokibart injection in an elderly diabetic patient: a case report. [PDF]

Front Med (Lausanne)
Yu M, Tian S, Meng F.
europepmc   +1 more source